Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (16 quarters reported)
$452M in Q4 2021 → $53.2M now. Hover for any quarter.
As reported for the quarter ended September 30, 2025. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Stoke Therapeutics Inc | 99.7% | Trimmed 31% | 2,256,181 | $53M |
| SS SPDR Ser Tr | 0.3% | Unchanged | 1,686 | $169K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended September 30, 2025 · filed October 29, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Stoke Therapeutics Inc | Trimmed | −1,000,000 | −$23.5M | 99.7% |
quarter ended June 30, 2025 · filed July 30, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Stoke Therapeutics Inc | Trimmed | −3,650,000 | −$41.4M | 99.6% |
quarter ended March 31, 2025 · filed May 06, 2025
No position changes this quarter.
quarter ended December 31, 2024 · filed February 05, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Stoke Therapeutics Inc | Trimmed | −2,000,000 | −$22.1M | 99.8% |
quarter ended September 30, 2024 · filed October 23, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Stoke Therapeutics Inc | Trimmed | −1,937,500 | −$23.8M | 99.8% |
quarter ended June 30, 2024 · filed August 05, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Stoke Therapeutics Inc | Trimmed | −3,600,000 | −$48.6M | 99.9% |
quarter ended March 31, 2024 · filed April 26, 2024
No position changes this quarter.
quarter ended December 31, 2023 · filed February 06, 2024
No position changes this quarter.
Loading...
